Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

ADHD, Stimulant Treatment, and Growth: A Longitudinal Study
Harstad, Elizabeth , Weaver, Amy L. , Katusic, Slavica K., Colligan, Robert C., Kumar, Seema , Chan, Eugenia, Voigt, Robert G. , Barbaresi, William J.

Pediatrics | September 2, 2014 | Volume: 134 | Issue: 4 | Pages: e935-e944

10.1542/peds.2014-0428 | PMID 25180281 Get It

BACKGROUND AND OBJECTIVE:There is ongoing concern that stimulant medications may adversely affect growth. In a sample of attention-deficit/hyperactivity disorder (ADHD) cases and controls from a population-based birth cohort, we assessed growth and the association between stimulant treatment and growth.METHODS:Subjects included childhood ADHD cases (N = 340) and controls (N = 680) from a 1976 to 1982 birth cohort (N = 5718). Height and stimulant treatment information were abstracted from medical records and obtained during a prospective, adult follow-up study. For each subject, a parametric penalized spline smoothing method modeled height over time, and the corresponding height velocity was calculated as the first derivative. Peak height velocity (PHV) age and magnitude were estimated from the velocity curves. Among stimulant-treated ADHD cases, we analyzed height Z scores at the beginning, at the end, and 24 months after the end of treatment.RESULTS:Neither ADHD itself nor treatment with stimulants was associated with differences in magnitude of PHV or final adult height. Among boys treated with stimulants, there was a positive correlation between duration of stimulant usage before PHV and age at PHV (r = 0.21, P = .01). There was no significant correlation between duration of treatment and change in height Z scores (r = −0.08 for beginning vs end change, r = 0.01 for end vs 24 months later change). Among the 59 ADHD cases treated for ≥3 years, there was a clinically insignificant decrease in mean Z score from beginning (0.48) to end (0.33) of treatment (P = .06).CONCLUSIONS:Our findings suggest that ADHD treatment with stimulant medication is not associated with differences in adult height or significant changes in growth.
Prolongation of a Prolonged QT
Snipelisky, David , Roberts, Maegan E. , Blackshear, Joseph L., Roberts, Maegan, Blackshear, Joseph, Roberts, Maegan E

JAMA Internal Medicine | September 1, 2014 | Volume: 174 | Issue: 11 | Pages: 1831

10.1001/jamainternmed.2014.4047 | PMID 25178485 Get It

Does My Patient Still Need This Central Venous Catheter?
Patel, Pratik B. , Aung, Htin , Post, Jason

JAMA Internal Medicine | September 1, 2014 | Volume: 174 | Issue: 11 | Pages: 1725

10.1001/jamainternmed.2014.4208 | PMID 25178306 Get It

Seroprevalence of Aquaporin-4–IgG in a Northern California Population Representative Cohort of Multiple Sclerosis
Pittock, Sean J. , Lennon, Vanda A. , Bakshi, Nandini, Shen, Ling, McKeon, Andrew , Quach, Hong , Briggs, Farren , Bernstein, Allan , Schaefer, Catherine , Barcellos, Lisa F. , Pittock, S J , McKeon, Andrew , Briggs, Farren Bs

JAMA Neurology | September 1, 2014 | Volume: 71 | Issue: 11 | Pages: 1433

10.1001/jamaneurol.2014.1581 | PMID 25178362 Get It

Lethal Sitting: Homo Sedentarius Seeks Answers
Levine, James A.

Physiology | September 1, 2014 | Volume: 29 | Issue: 5 | Pages: 300-301

10.1152/physiol.00034.2014 | PMID 25180258 Get It

Development of a consensus protocol to quantify primate anti‐non‐ G al xenoreactive antibodies using pig aortic endothelial cells
Azimzadeh, Agnes M. , Byrne, Guerard W. , Ezzelarab, Mohamed , Welty, Emily, Braileanu, Gheorghe, Cheng, Xiangfei , McGregor, Christopher G.A. , Pierson, Richard N. , Ezzelarab, Mohamed B. , Robson, Simon Christopher , Cooper, David K. C.

Xenotransplantation | September 1, 2014 | Volume: 21 | Issue: 6 | Pages: 555-566

10.1111/xen.12125 | PMID 25176173 Get It

Abstract Background Scientists working in the field of xenotransplantation do not employ a uniform method to measure and report natural and induced antibody responses to non‐ G alα(1,3) G al (non‐ G al) epitopes. Such humoral responses are thought to be particularly pathogenic after transplantation of vascularized Gal TKO pig organs and having a more uniform assay and reporting format would greatly facilitate comparisons between laboratories. Methods Flow cytometry allows examination of antibody reactivity to intact antigens in their natural location and conformation on cell membranes. We have established a simple and reproducible flow cytometric assay to detect antibodies specific for non‐ G al pig antigens using primary porcine aortic endothelial cells ( pAEC s) and cell culture‐adapted pAEC cell lines generated from wild type and α1,3galactosyl transferase knockout (Gal TKO ) swine. Results The consensus protocol we propose here is based on procedures routinely used in four xenotransplantation centers and was independently evaluated at three sites using shared cells and serum samples. Our observation support use of the cell culture‐adapted Gal TKO pAEC KO :15502 cells as a routine method to determine the reactivity of anti‐non‐ G al antibodies in human and baboon serum. Conclusions We have developed an assay that allows the detection of natural and induced non‐Gal xenoreactive antibodies present in human or baboon serum in a reliable and consistent manner. This consensus assay and format for reporting the data should be accessible to laboratories and will be useful for assessing experimental results between multiple research centers. Adopting this assay and format for reporting the data should facilitate the detection, monitoring, and detailed characterization of non‐ G al antibody responses.
Cloning and expression of porcine β1,4 N‐acetylgalactosaminyl transferase encoding a new xenoreactive antigen
Byrne, Guerard W. , Du, Zeji , Stalboerger, Paul G., Kogelberg, Heide, McGregor, Christopher G.A.

Xenotransplantation | September 1, 2014 | Volume: 21 | Issue: 6 | Pages: 543-554

10.1111/xen.12124 | PMID 25176027 Get It

Abstract Background Xenograft rejection of pigs organs with an engineered mutation in the GGTA‐1 gene (GTKO) remains a predominantly antibody mediated process which is directed to a variety of non‐Gal protein and carbohydrate antigens. We previously used an expression library screening strategy to identify six porcine endothelial cell cDNA s which encode pig antigens that bind to IgG induced after pig‐to‐primate cardiac xenotransplantation. One of these gene products was a glycosyltransferase with homology to the bovine β1,4 N‐acetylgalactosaminyltransferase (B4GALNT2). We now characterize the porcine B4GALNT2 gene sequence, genomic organization, expression, and functional significance. Methods The porcine B4GALNT2 cDNA was recovered from the original library isolate, subcloned, sequenced, and used to identify a bacterial artificial chromosome (BAC) containing the entire B4GALNT2 locus from the Children's Hospital Oakland Research Institute BACPAC Resource Centre (#AC173453). PCR primers were designed to map the intron/exon genomic organization in the BAC clone. A stable human embryonic kidney (HEK) cell line expressing porcine B4GALNT2 (HEK‐B4T) was produced. Expression of porcine B4GALNT2 in HEK‐B4T cells was characterized by immune staining and siRNA transfection. The effects of B4GALNT2 expression in HEK‐B4T cells was measured by flow cytometry and complement mediated lysis. Antibody binding to HEK and HEK‐B4T cells was used to detect an induced antibody response to the B4GALNT2 produced glycan and the results were compared to GTKO PAEC specific non‐Gal antibody induction. Expression of porcine B4GALNT2 in pig cells and tissues was measured by qualitative and quantitative real time reverse transcriptase PCR and by Dolichos biflorus agglutinin (DBA) tissue staining. Results The porcine B4 GALNT 2 gene shares a conserved genomic organization and encodes an open reading frame with 76 and 70% amino acid identity to the human and murine B4 GALNT 2 genes, respectively. The B4 GALNT 2 gene is expressed in porcine endothelial cells and shows a broadly distributed expression pattern. Expression of porcine B4 GALNT 2 in human HEK cells ( HEK ‐B4T) results in increased binding of antibody to the B4 GALNT 2 enzyme, and increased reactivity with anti‐Sd a and DBA . HEK ‐B4T cells show increased sensitivity to complement mediated lysis when challenged with serum from primates after pig to primate cardiac xenotransplantation. In GTKO and GTKO : CD 55 cardiac xenotransplantation recipients there is a significant correlation between the induction of a non‐Gal antibody, measured using GTKO PAEC s, and the induction of antibodies which preferentially bind to HEK ‐B4T cells. Conclusion The functional isolation of the porcine B4 GALNT 2 gene from a PAEC expression library, the pattern of B4 GALNT 2 gene expression and its sensitization of HEK ‐B4T cells to antibody binding and complement mediated lysis indicates that the enzymatic activity of porcine B4 GALNT 2 produces a new immunogenic non‐Gal glycan which contributes in part to the non‐Gal immune response detected after pig‐to‐baboon cardiac xenotransplantation.
Resection of cervical ependymoma
Morales-Valero, Saul F., Krauss, William E. , Campero, Mario, Marsh, W. Richard , Lanzino, Giuseppe

Neurosurgical Focus | September 1, 2014 | Volume: 37 | Issue: v2supplement | Pages: Video14

10.3171/2014.v3.focus14378 | PMID 25175575 Get It

Intramedullary ependymomas are surgically curable tumors. However, their surgical resection poses several challenges. In this intraoperative video we illustrate the main steps for the surgical resection of a cervical intramedullary ependymoma. These critical steps include: adequate exposure of the entire length of the tumor; use of the intraoperative ultrasound; identification of the posterior median sulcus and separation of the posterior columns; Identification of the plane between the spinal cord and the tumor; mobilization and debulking of the tumor and disconnection of the vascular supply (usually from small anterior spinal artery branches). Following these basic steps a complete resection can be safely achieved in many cases. The video can be found here: http://youtu.be/QMYXC_F4O4U .
Introduction: Strategies for management and outcomes of arteriovenous malformations
Spetzler, Robert F., Giannotta, Steven L. , Meyer, Fredric B. , Lawton, Michael T. , Cohen‐Gadol, Aaron , Russin, Jonathan Joseph

Neurosurgical Focus | September 1, 2014 | Volume: 37 | Issue: 3 | Pages: Introduction

10.3171/2014.7.focus14421 | PMID 25175448 Get It

Are parenchymal AVMs congenital lesions?
Morales-Valero, Saul F., Bortolotti, Carlo , Sturiale, Carmelo Lucio , Lanzino, Giuseppe

Neurosurgical Focus | September 1, 2014 | Volume: 37 | Issue: 3 | Pages: E2

10.3171/2014.6.focus14234 | PMID 25175439 Get It

A long-held dogma in neurosurgery is that parenchymal arteriovenous malformations (AVMs) are congenital. However, there is no strong evidence supporting this theory. An increasing number of documented cases of de novo formation of parenchymal AVMs cast doubt on their congenital nature and suggest that indeed the majority of these lesions may form after birth. Further evidence suggesting the postnatal development of parenchymal AVMs comes from the exceedingly rare diagnosis of these lesions in utero despite the widespread availability of high-resolution imaging modalities such as ultrasound and fetal MRI. The exact mechanism of AVM formation has yet to be elucidated, but most likely involves genetic susceptibility and environmental triggering factors. In this review, the authors report 2 cases of de novo AVM formation and analyze the evidence suggesting that they represent an acquired condition.